To better understand which social media platforms Americans use, Pew Research Center surveyed 5,022 U.S. adults from Feb. 5 to June 18, 2025. SSRS conducted this National Public Opinion Reference ...
The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The ...
Roanoke, Virginia — As a 10-year-old, Autumn Bushman loved to perform. The fourth-grade cheerleader from Salem, Virginia, was a bundle of energy. "She really turned my living room into a dance floor," ...
Card-reading contact lenses, X-ray poker tables, trays of poker chips that read cards, hacked shuffling machines that predict hands. The technology alleged to have been used to execute a multistate, ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Teachers’ and students’ use of artificial intelligence in K-12 classrooms is increasing at a rapid pace, prompting serious concerns about the potentially negative effects on students, a new report ...
Chances are, if you need a new tool or are looking to build out a collection, DeWalt has got you covered. The brand has been around for ages, winning over the business of DIYers and professionals ...
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, ...
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune misled investors about the prospects of its IGNYTE trial for RP1 (vusolimogene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback